New results from one of the largest ever vapour product studies, which analysed BAT’s flagship vapour brand Vuse, have shown adult consumers using Vuse demonstrated significantly better results for biomarkers relevant to smoking-related diseases than smokers.
BAT said the findings, published in the journal of Internal and Emergency Medicine, adds to the scientific evidence around vaping as a reduced-risk products category and highlights the value of Vuse in tobacco harm reduction.
The study compared clinical measurements from exclusive Vuse consumers with smokers. The results of the study show that participating Vuse consumers had favourable differences in biomarkers of exposure (BoE) and biomarkers of potential harm (BoPH) relevant to smoking-related diseases when compared to smokers.
Vuse users have shown significantly lower biomarkers of exposure for priority cigarette smoke toxicants as defined by the World Health Organization (WHO). The data also showed favourable differences between Vuse consumers and smokers across all biomarkers of potential harm measured, with three being statistically significant.
“Vaping continues to grow in importance, as adult smokers seek reduced-risk alternative nicotine products. That is why these results are so important for Vuse, BAT and consumers, as they allow us to better understand the positive real-world impact of vaping compared to smoking,” Dr James Murphy, Director, Research and Science at BAT, said.
“The research shows a clear difference between those using Vuse compared to smokers and reinforces the reduced risk potential and role of vapour in Tobacco Harm Reduction.”
Vapour products are the most widely studied and accepted alternative tobacco and nicotine products worldwide. BAT said its scientific vapour product data have been published in more than 80 peer-reviewed journals and add to the weight of evidence supporting the category’s role in tobacco harm reduction.
The clinical study of participating Vuse consumers, smokers, former smokers and never smokers based in the UK, aged between 19-55 years old, provides comprehensive analysis of 17 biomarkers of exposure (BoE) to priority cigarette smoke toxicants, biomarkers of potential harm (BoPH) and physiological measures relevant to cardiovascular conditions, respiratory diseases and cancer.
In addition to the wide range of BoE and BoPH assessed, another advantage of this study design was the relatively large number of participants (n-213 recruited), larger than any prior vapour studies of this kind.
Volumatic offers integration with the G4S CASH360 integration
Alex Rimmer
